Binetrakin
- Generic Name
- Binetrakin
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 207137-56-2
- Unique Ingredient Identifier
- 751635Z921
- Background
Binetrakin has been used in trials studying the treatment of HIV Infections, Sarcoma, Kaposi, Non-Hodgkin's Lymphoma (NHL), Myelodysplastic Syndrome (MDS), and Leukemia, Acute Myelogenous (AML), among others.
- Associated Conditions
- -
- Associated Therapies
- -
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic ...
CHMP recommends Dupixent for EoE in children aged 1-11, based on Phase 3 trial showing histological remission. If approved, it would be the first EU treatment for this age group.
Dupixent® (dupilumab) Recommended for EU Approval by the
CHMP recommends Dupixent for EoE in children aged 1-11, based on Phase 3 trial showing histological remission. If approved, it would be the first EU treatment for this age group.
Sanofi/Regeneron's Dupixent granted FDA approval for adolescents with CRSwNP
Sanofi and Regeneron’s Dupixent approved by FDA as add-on maintenance treatment for adolescents with chronic rhinosinusitis with nasal polyps (CRSwNP), ages 12-17, expanding previous approval for ages 18 and older. Dupixent, a monoclonal antibody, inhibits interleukin-4 and interleukin-13 pathways, improving symptoms and reducing need for systemic corticosteroids or surgery.
Dupixent gains FDA approval for expanded use in adolescents with CRSwNP
Regeneron Pharmaceuticals and Sanofi receive FDA approval for Dupixent as add-on treatment for adolescents with CRSwNP, based on Phase 3 trials showing improvements in nasal congestion, polyp size, and sense of smell, and reduced need for corticosteroids or surgery.
Dupixent receives FDA approval as first CRSwNP treatment
FDA expands Dupixent approval for adolescents (12-17) with uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP), based on trials showing significant improvements in symptoms.
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents
FDA approves Dupixent for adolescents aged 12-17 with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP), expanding from initial approval for adults. Dupixent, a biologic inhibiting IL-4 and IL-13 pathways, demonstrated efficacy in trials, improving nasal congestion, polyp size, and sense of smell, while reducing corticosteroid use and surgery.
NHS chiefs to roll out new drugs for lethal lung disease that took life of Star Trek actor
Dupilumab, a new drug for COPD, significantly reduces symptoms and improves lung function, awaiting NHS approval.
FDA Approves Dupilumab Label Expansion with Indication for CRSwNP in Adolescents
The FDA approved dupilumab (Dupixent) as add-on maintenance therapy for adolescents aged 12-17 with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP), marking the first biologic treatment for this age group. Dupilumab, a monoclonal antibody targeting IL-4 and IL-13 pathways, significantly improves symptoms and reduces the need for systemic corticosteroids or surgery, with a safety profile consistent with its known effects.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath